TWI922674B - Ａｘｌ抑制劑化合物及其用途 - Google Patents
Ａｘｌ抑制劑化合物及其用途Info
- Publication number
- TWI922674B TWI922674B TW111118944A TW111118944A TWI922674B TW I922674 B TWI922674 B TW I922674B TW 111118944 A TW111118944 A TW 111118944A TW 111118944 A TW111118944 A TW 111118944A TW I922674 B TWI922674 B TW I922674B
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- group
- halogen
- compound
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191636P | 2021-05-21 | 2021-05-21 | |
| US63/191,636 | 2021-05-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202313603A TW202313603A (zh) | 2023-04-01 |
| TWI922674B true TWI922674B (zh) | 2026-04-21 |
Family
ID=82115819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111118944A TWI922674B (zh) | 2021-05-21 | 2022-05-20 | Ａｘｌ抑制劑化合物及其用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240226115A1 (enExample) |
| EP (1) | EP4341262A1 (enExample) |
| JP (1) | JP7876557B2 (enExample) |
| CN (1) | CN117337288A (enExample) |
| TW (1) | TWI922674B (enExample) |
| WO (1) | WO2022246179A1 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR129722A1 (es) | 2022-06-28 | 2024-09-18 | Arcus Biosciences Inc | Compuestos inhibidores de axl |
| EP4554680A1 (en) | 2022-07-15 | 2025-05-21 | Arcus Biosciences, Inc. | Inhibitors of hpk1 and methods of use thereof |
| WO2024020034A1 (en) | 2022-07-20 | 2024-01-25 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| TW202421150A (zh) | 2022-09-14 | 2024-06-01 | 美商阿克思生物科學有限公司 | 艾魯美冷之分散體 |
| EP4602041A1 (en) | 2022-10-14 | 2025-08-20 | Arcus Biosciences, Inc. | Hpk1 inhibitors and methods of use thereof |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| EP4705292A1 (en) | 2023-05-05 | 2026-03-11 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| WO2024243502A1 (en) | 2023-05-25 | 2024-11-28 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| CN121285743A (zh) | 2023-06-02 | 2026-01-06 | 艾库斯生物科学有限公司 | 用于预测癌症治疗功效的生物标志物 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| WO2025054339A1 (en) | 2023-09-08 | 2025-03-13 | Arcus Biosciences, Inc. | Triazolopyridine compounds as inhibitors of kit |
| WO2025072330A1 (en) | 2023-09-26 | 2025-04-03 | Arcus Biosciences, Inc. | Kit inhibitor compounds and methods of use thereof |
| EP4788432A1 (en) | 2023-10-06 | 2026-08-12 | Arcus Biosciences, Inc. | Cbl-b inhibitors and methods of use thereof |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| US12384773B2 (en) | 2023-11-02 | 2025-08-12 | Arcus Biosciences, Inc. | Thiazole compounds and methods of use thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006759A1 (en) | 2024-06-28 | 2026-01-02 | Arcus Biosciences, Inc. | Pharmaceutical compositions, dosage forms, and methods of making and using same |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020103896A1 (en) * | 2018-11-22 | 2020-05-28 | Beigene, Ltd. | Pyrrolo[2,3-b]pyridines as hpk1 inhibitor and uses thereof |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール，インク． | Ｇｉｔｒ結合分子およびその使用 |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| IN2015DN02826A (enExample) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| DK2510010T3 (en) | 2009-12-10 | 2015-12-14 | Hoffmann La Roche | Antibodies that bind to human CSF1R extracellular domain 4 and their use |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| RU2617971C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| EP3943154A1 (en) | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| LT3399984T (lt) | 2016-01-08 | 2023-11-10 | Arcus Biosciences, Inc. | 5'-nukleotidazės, ekto moduliatoriai ir jų panaudojimas |
| WO2018067424A1 (en) | 2016-10-03 | 2018-04-12 | Arcus Biosciences, Inc. | Inhibitors of adenosine 5'-nucleotidase |
| CN110022881B (zh) | 2016-11-18 | 2023-05-02 | 艾库斯生物科学有限公司 | Cd73介导的免疫抑制的抑制剂 |
| MX389798B (es) | 2017-01-20 | 2025-03-20 | Arcus Biosciences Inc | Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer. |
| EP3618829B1 (en) | 2017-05-05 | 2023-06-07 | Arcus Biosciences, Inc. | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
| AU2019312296B2 (en) | 2018-07-27 | 2025-05-29 | Arcus Biosciences, Inc. | Pyridone A2R antagonists |
| ES3053198T3 (en) | 2018-08-27 | 2026-01-20 | Arcus Biosciences Inc | Cd73 inhibitors |
| EP3880685B1 (en) | 2018-11-16 | 2025-06-18 | Arcus Biosciences, Inc. | Inhibitors of arg1 and/or arg2 |
| AU2020288610A1 (en) | 2019-06-04 | 2022-01-27 | Arcus Biosciences, Inc. | 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds |
| TWI848141B (zh) * | 2019-07-04 | 2024-07-11 | 英屬開曼群島商百濟神州有限公司 | 及其用途 |
| EP4069212A4 (en) | 2019-12-04 | 2024-03-06 | Arcus Biosciences, Inc. | INHIBITORS OF HIF-2ALPHA |
| CA3173831A1 (en) | 2020-03-19 | 2021-09-23 | Arcus Biosciences, Inc. | Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha |
-
2022
- 2022-05-20 EP EP22731890.4A patent/EP4341262A1/en active Pending
- 2022-05-20 US US18/555,971 patent/US20240226115A1/en active Pending
- 2022-05-20 JP JP2023571841A patent/JP7876557B2/ja active Active
- 2022-05-20 CN CN202280034431.2A patent/CN117337288A/zh active Pending
- 2022-05-20 WO PCT/US2022/030230 patent/WO2022246179A1/en not_active Ceased
- 2022-05-20 TW TW111118944A patent/TWI922674B/zh active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020103896A1 (en) * | 2018-11-22 | 2020-05-28 | Beigene, Ltd. | Pyrrolo[2,3-b]pyridines as hpk1 inhibitor and uses thereof |
Non-Patent Citations (1)
| Title |
|---|
| 期刊 Myers SH, et al. "AXL inhibitors in cancer: a medicinal chemistry perspective" J MED CHEM 59(8): 2016; 3593-3608 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022246179A1 (en) | 2022-11-24 |
| US20240226115A1 (en) | 2024-07-11 |
| CN117337288A (zh) | 2024-01-02 |
| EP4341262A1 (en) | 2024-03-27 |
| JP2024521712A (ja) | 2024-06-04 |
| JP7876557B2 (ja) | 2026-06-19 |
| TW202313603A (zh) | 2023-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202313603A (zh) | Axl抑制劑化合物 | |
| JP7843299B2 (ja) | Ａｘｌ化合物 | |
| TWI888507B (zh) | 作為HIF-2α抑制劑的四氫萘及四氫喹啉化合物 | |
| TWI857071B (zh) | 2,3,5-三取代吡唑并[1,5-a]嘧啶化合物 | |
| TWI916379B (zh) | 作為jak2 v617f抑制劑之三環脲化合物 | |
| ES2971271T3 (es) | Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer | |
| TW202202504A (zh) | Cd73化合物 | |
| CA3163338A1 (en) | Inhibitors of hif-2alpha | |
| TWI829857B (zh) | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 | |
| JP7384535B2 (ja) | キナゾリン化合物並びにその調製方法、使用及び医薬組成物 | |
| TW202428272A (zh) | 作為ｄｇｋ抑制劑之雜芳基氟烯烴 | |
| WO2022187518A1 (en) | Substituted 4-piperidinyl-imidazo[4,5-b]pyridines and related compounds and their use in treating medical conditions | |
| TWI924689B (zh) | 嘧啶酮類化合物及其用途 | |
| TW202416950A (zh) | 雜芳基甲醯胺及相關gpr84拮抗劑及其用途 | |
| HK40105873A (en) | Axl inhibitor compounds | |
| HK40105246A (en) | Axl compounds | |
| HK40068316B (zh) | 2，3，5-三取代吡唑并[1，5-a]嘧啶化合物 | |
| HK40126571A (en) | Heteroaryl carboxamide and related gpr84 antagonists and uses thereof | |
| EA051854B1 (ru) | Тетралиновые и тетрагидрохинолиновые соединения в качестве ингибиторов hif-2-альфа | |
| TW202432563A (zh) | Irak降解劑及其用途 | |
| HK40068316A (en) | 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds |